CoChat

Amantadine as augmentation therapy in the management of treatment-resistant depression

Stryjer, Rafael, Strous, Rael D., Shaked, Ginette, Bar, Faina, Feldman, Boris, Kotler, Moshe, Polak, Lea, Rosenzcwaig, Silvio, Weizman, Abraham · 2003 · International Clinical Psychopharmacology
Cited by 103

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Treatment-resistant depression is an important clinical problem presenting a major challenge to clinical psychiatry. While several strategies have been attempted, including medication switch, antidepressant polypharmacy and various augmentative regimens, success remains limited. Amantadine (AMN), an agent traditionally used in the treatment and prophylaxis of influenza, is now known to exhibit prominent effects at the level of dopaminergic, monoamine oxidase and N-methyl-D-aspartate systems. The present reports on the efficacy of AMN as augmentation to standard antidepressant treatment in patients with treatment-resistant depression. Eight patients with treatment-resistant depression consented to receive AMN, titrated up to a dose of 300 mg, over a period of 4 weeks in a non-blinded fashion. Improvement in both depression and anxiety scores were observed from week 1, with patients exhibiting improvement of depressive scores of up to 49% by study completion. Females appeared to exhibit a stronger response, and within a shorter period of time. Side-effects reported included dry mouth and sedation. AMN appears to demonstrate efficacy as a safe and effective augmentative agent in treatment-resistant depression. Further studies are clearly mandated to test these preliminary observations in a double-blinded manner.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/00004850-200303000-00005

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 103

Metadata

Authors
Stryjer, R., Strous, R. D., Shaked, G., Bar, F., Feldman, B., Kotler, M., Polak, L., Rosenzcwaig, S., & Weizman, A.
Venue
International Clinical Psychopharmacology
Published
2003-03
Volume
18
Issue
2
Pages
93-96
ISSN
0268-1315 (ISSN-L)
OpenAlex
W1977073959
Cited by
103
References
2
FWCI
7.18
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Amantadine as augmentation therapy in the management of treatment-resistant depression. https://app.cochat.ai/papers/10.1097/00004850-200303000-00005
The paper
Stryjer, R., Strous, R. D., Shaked, G., Bar, F., Feldman, B., Kotler, M., Polak, L., Rosenzcwaig, S., & Weizman, A. (2003). Amantadine as augmentation therapy in the management of treatment-resistant depression. International Clinical Psychopharmacology. https://doi.org/10.1097/00004850-200303000-00005

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.